Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta To Launch First Commercial Drug Baxdela Independently

Executive Summary

Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.

You may also be interested in...



Melinta: A Pure-Play Antibiotics Specialist Rises

CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market, following the acquisition of The Medicines Co.'s anti-infectives franchise and a reverse merger with Cempra last year.

Melinta Expands Portfolio, TMC Narrows Focus To LDL Reduction With Anti-Infective Deal

A transaction bringing newly public Melinta three anti-infective products and a related sales force from The Medicines Co. will enable the latter to downsize and focus on its Phase III PCSK9 inhibitor inclisiran.

Merger With Cempra Takes Melinta Public, Will Help Launch Baxdela

In all-stock transaction, troubled Cempra will merge with privately held Melinta to create a fully integrated anti-infectives company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel